Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Patient enrollment completed in phase IIa trial of Onyvax-P

April 17, 2003

AG-858/Gleevec combination therapy subject of new phase II trial in CML

April 15, 2003

Pharmexa seeks approval in Europe for phase II HER-2 DNA AutoVac trial

April 10, 2003

HYB-2055 enters the clinic

April 7, 2003

New patent broadens protection for Virulizin

April 7, 2003

Oxford BioMedica cleared to begin phase II trial of TroVax in colorectal cancer

April 3, 2003

Initiation of first of two expanded phase II trials of GVAX lung cancer vaccine

April 3, 2003

Pharmexa applies to begin phase I trial of HER-2 Protein AutoVac product

April 2, 2003

MediGene discontinues development of CVLP tumor vaccine

March 28, 2003

Protein Design Labs licenses SMART M195 antibody to Actinium

March 20, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...